Asset Details
Do you wish to reserve the book?
A New Era for Anticoagulation in Atrial Fibrillation
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
A New Era for Anticoagulation in Atrial Fibrillation
Do you wish to request the book?
A New Era for Anticoagulation in Atrial Fibrillation
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
A New Era for Anticoagulation in Atrial Fibrillation
2011
Overview
For more than 50 years, warfarin has been the primary medication used to reduce the risk of thromboembolic events in patients with atrial fibrillation. Despite its clinical efficacy, warfarin has multiple, well-known limitations, including numerous interactions with other drugs and the need for regular blood monitoring and dose adjustments. Thus, clinicians and patients have been eager to embrace alternative oral anticoagulants that are equally efficacious but easier to administer.
In this issue of the
Journal,
Granger and colleagues report the impressive primary results of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial (ARISTOTLE; ClinicalTrials.gov . . .
Publisher
Massachusetts Medical Society
Subject
/ Anticoagulants - therapeutic use
/ Atrial Fibrillation - drug therapy
/ Benzimidazoles - therapeutic use
/ beta-Alanine - analogs & derivatives
/ beta-Alanine - therapeutic use
/ Humans
/ Morpholines - therapeutic use
/ Stroke
/ Stroke - prevention & control
/ Thiophenes - therapeutic use
/ Thromboembolism - prevention & control
/ Trends
/ Warfarin
